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Abstract In drug discovery and development, classical compartment models and
physiologically based pharmacokinetic (PBPK) models are successfully used to
analyze and predict the pharmacokinetics of drugs. So far, however, both approa-
ches are used exclusively or in parallel, with little to no cross-fertilization. An
approach that directly links classical compartment and PBPK models is highly
desirable. We derived a new mechanistic lumping approach for reducing the
complexity of PBPK models and establishing a direct link to classical compartment
models. The proposed method has several advantages over existing methods: Per-
fusion and permeability rate limited models can be lumped; the lumped model
allows for predicting the original organ concentrations; and the volume of distri-
bution at steady state is preserved by the lumping method. To inform classical
compartmental model development, we introduced the concept of a minimal lumped
model that allows for prediction of the venous plasma concentration with as few
compartments as possible. The minimal lumped parameter values may serve as
initial values for any subsequent parameter estimation process. Applying our
lumping method to 25 diverse drugs, we identified characteristic features of lumped
models for moderate-to-strong bases, weak bases and acids. We observed that for
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acids with high protein binding, the lumped model comprised only a single com-
partment. The proposed lumping approach established for the first time a direct
derivation of simple compartment models from PBPK models and enables a
mechanistic interpretation of classical compartment models.
Keywords Classical model  Compartment PK model 
Physiologically based pharmacokinetics  PBPK  Mechanistic lumping 
Volume of distribution  Minimal lumped model  Transfer of knowledge
Introduction
During preclinical and clinical drug development, a variety of in vitro and in vivo
data are collected to investigate the pharmacokinetics (PK) and pharmacodynamics
of a drug candidate, e.g., [1, 2]. A common approach to examine the PK of a drug is
by classical compartmental analysis, e.g., [3, 4]. Usually, a low dimensional
compartment model is fitted to in vivo plasma or blood data and then used to derive
key characteristics (AUC, CL, tmax, Cmax etc.) or for extrapolation (different
routes of administration, multiple dosing, allometric scaling). Another approach to
investigate the PK of a drug is whole-body physiologically based pharmacokinetic
(PBPK) modeling [5–9]. PBPK models represent relevant absorption, distribution,
metabolism and excretion (ADME) processes in a mechanistic way and allow for
the integration of diverse in vitro and in vivo data. PBPK models can be used to
predict plasma concentration profiles prior to any in vivo studies, solely based on in
vitro data. If gradually refined and evaluated against preclinical and early clinical
data, a PBPK model can be seen as reflecting part of the current knowledge about a
drug candidate, stated in the language of mathematics. Such models, however, are
less suitable for estimation of individual parameters as part of, e.g., in population
analysis of clinical trails [10] due to their complexity.
So far, the classical compartmental PK and the physiologically-based PK
approach are used independently or in parallel, with little to no overlap or cross-
fertilization. In particular, classical compartmental model development does not
directly benefit from the knowledge that is present in a PBPK model. An approach
that establishes the link between mechanistic PBPK models and classical
compartmental models is therefore highly desirable.
The objective of this article is to translate prior knowledge on the PK of a
compound given in form of a whole-body PBPK model into the development of
classical compartmental models in different stages of the drug development process.
For a given drug, we determine essential characteristics of PK compartment models
by lumping of the detailed whole-body PBPK model. Our approach is based on a
new lumping method that determines the number and composition of lumped
compartments based on the PK profiles in the distribution and elimination phase.
In literature, several approaches for the reduction and lumping of PBPK models
have been proposed [11–14]. These methods, however, rely on much more
restrictive lumping rules that have difficulties to justify lumping a detailed PBPK
model to, e.g., a 1- or 2-compartment model. Such low dimensional models,
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however, are frequently used in all stages of the development process to describe
clinical data, e.g., [10]. In addition, only the concentration of the lumped
compartments are predicted by the existing lumping approaches, while no link to
the drug concentration of the original organs and tissues is established (unless this
tissue is left unlumped, as suggested in [12]).
Our proposed new lumping procedure overcomes these limitations. It exploits the
fact that drug concentrations in different compartments of the whole-body PBPK
model are often strongly kinetically dependent of each other. We quantify and
exploit this dependence to establish the lumped model and to relate the lumped
concentrations back to the original ones. Using parametrization of PBPK models
based on recent methods to a priori predict tissue-partition coefficients [15–18], we
observe characteristic features for moderate-to-strong bases, weak bases and acids.
For acids with a low fraction unbound in plasma (fup), e.g., a 1-compartment model
was sufficient to predict the concentration-time course of all 13 tissues and organs in
the original PBPK model.
Material and methods
Generic PBPK model
A general introduction to PBPK modeling can be found, e.g., in [5–7, 9, 19–21]. Our
detailed PBPK model comprised 13 compartments representing important tissues,
organs or other spaces within the human body (see Fig. 1). The model accounts for
the anatomical compartments arterial and venous blood, lung, adipose tissue, bone,
brain, gut, heart, kidneys, liver, muscle, skin, and spleen. For simplicity, we used the
subscript ’tis’ to refer to tissues and organs.
As typically done in the generic setting and in the absence of more specific
information, we assume that the drug distributes within the body via transport by the
blood flow and via passive diffusion homogeneously into organs and tissues, and
that the drug is metabolized in the liver. In the presence of more specific
information, the generic PBPK model can be adapted accordingly, e.g., to account
for active transport processes, excretion by the kidneys, specific protein binding,
saturable metabolism etc.
Based on the perfusion-limited (well-stirred) tissue model, the following
differential equation (ODE) describes the distribution processes in each non-
eliminating organ/tissue:
Vtis
d
dt
Ctis ¼ Qtis  Cin  Ctis
Ktis
 
; ð1Þ
where Ctis represents the total drug concentration in the organ/tissue and Cin rep-
resents the influent blood concentration. In most cases, this is the arterial blood
concentration (see below for more details). Vtis and Qtis denote the tissue volume
and blood flow, respectively. The tissue-to-blood partition coefficient, Ktis, relates
the steady state tissue drug concentration to the steady state blood concentration.
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Ktis ¼ Css;tis
Css;blood
: ð2Þ
Thus, in Eq. 1, the term Ctis/Ktis represents the blood concentration leaving the
compartment. Since metabolism is assumed to occur in the liver, the corresponding
ODE is:
Vliv
d
dt
Cliv ¼ Qliv  Cin  Cliv
Kliv
 
 CLintCliv; ð3Þ
where CLint denotes the hepatic intrinsic clearance. Alternatively, some PBPK
models assume that only the unbound concentration in the liver tissue Cu,liv can be
metabolized, resulting in a term CLint  Cu,liv instead of CLint  Cliv. Assuming that
Cu,liv = fuliv  Cliv, this can easily be integrated in our setting by changing CLint to
CLint  fuliv.
For the artery and vein compartments the ODEs are
Vart
d
dt
Cart ¼ Qco  Cin  Cartð Þ; ð4Þ
Vven
d
dt
Cven ¼ Qco  Cin  Cvenð Þ; ð5Þ
where Qco denotes the cardiac output. For all organs except lung, liver, artery and
vein, it is Cin = Cart. For the lung, it is Cin = Cven, and for the artery, it is
Fig. 1 Organ and tissue
topology of the generic 13
compartment PBPK model. In
the generic model, only hepatic
elimination is assumed. If
knowledge about further routes
of elimination (e.g., renal) is
available, this can easily be
integrated
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Cin = Clun. The influent liver and venous blood concentrations are defined by the
blood flow weighted sums of all organ concentrations that supply these compart-
ments. For liver, it is
Cin ¼ 1
Qliv
X
tis
Qtis
Ctis
Ktis
; ð6Þ
where the sum is take of spleen, gut and the arterial hepatic vein. For the vein it is
Cin ¼ 1
Qco
X
tis
Qtis
Ctis
Ktis
; ð7Þ
where the sum is taken of adipose, bone, brain, heart, kidneys, muscle, skin and the
liver.
Frequently used routes of drug administration are a bolus i.v. administration, an
i.v. infusion and a p.o. administration. This requires to extend the venous blood and
the liver ODE correspondingly. For a bolus i.v. administration, the initial condition
C(t = 0) for the system of ODEs is set to Cven(0) = dose/Vven, while all other initial
concentrations are set to zero. For an i.v. infusion, the venous ODE has to be
changed to:
Vven
d
dt
Cven ¼ Qven  Cin  Cvenð Þ þ riv; ð8Þ
where ‘riv’ denotes the mass influx due to an i.v. infusion given by
riv ¼ dose=DT ; t 2 ½T0; T0 þ DT0; otherwise;

ð9Þ
with starting time T0 and duration DT . In the case of p.o. drug administration, the
liver ODE has to be amended to
Vliv
d
dt
Cliv ¼ Qliv  Cin  Cliv
Kliv
 
 CLintCliv þ rpo FFGð Þ; ð10Þ
where ‘rpoðFFGÞ’ denotes the mass influx due to a p.o. administration. For a first order
absorption model it is:
rpo FFGð Þ ¼ dose  FFG  ka  ekat; ð11Þ
where ka denotes the first order absorption rate constant and FFG denotes the
product of the fraction absorbed FF and fraction not metabolized in the gut
FG = (1 - Egut). Using the hepatic extraction ratio Ehep (see Eq. 16 below), we
have
Fbio ¼ ð1  EhepÞ  ð1  EgutÞ  FF|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
FFG
; ð12Þ
where Fbio denotes the bioavailability of the compound. We define for later
reference
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rpoðFbioÞ ¼ dose  Fbio  ka  ekat; ð13Þ
where the oral absorption model already accounts for hepatic extraction.
Parametrization
A whole-body PBPK model requires species-specific physiological and anatomical
parameters in addition to drug-specific data. Tissue volumes per kg body weight and
blood flows in % of cardiac output are given in Table 1. We consider the standard
male human with a body weight of 73 kg and a cardiac output of 6.5 l/min [22, 23].
Physicochemical and pharmacokinetic data for a number of drugs from different
classes are summarized in Table 3. We use the drug Lidocaine to demonstrate our
general approach. It is commonly used as an antiarrythmic drug in the treatment of
ventricular arrhythmias [3, 34]. Its organ-specific tissue-to-blood partition coeffi-
cients, Ktis, are listed in Table 1, right column. We determined Ktis from the tissue-
to-unbound plasma partition coefficients, Kutis, via the relation
Ktis ¼ fu
p
B:P
Kutis; ð14Þ
where fup and B:P are the fraction unbound in plasma and the blood-to-plasma ratio,
respectively. We predicted Kutis based on the model proposed by Rodgers et al.
[15–18] to a priori predict tissue-to-unbound plasma partition coefficients. The
quality of the a priori methods to predict tissue-to-unbound drug partition
coefficients is 84–89% (within factor 3 of experimental values, reported for the
species rat) [15, 17]. Situations that can give rise to under- or over-predictions of
Kutis values include active transport processes, non-linear pharmacokinetics and
binding to tissue constituents not accommodated in the mechanistic equations. In
addition, insufficiently long infusion times for the experimental determination of the
tissue-to-unbound plasma partition coefficients result in deviations between in silico
and in vivo values. Drug-specific input parameters are fup, pKa, logPow and
potentially B:P.
While often the intrinsic clearance is used to model hepatic metabolism in whole-
body PBPK models, clinical studies and associated PK compartment models use the
hepatic blood clearance CLblood. Employing the widely-used well-stirred liver
model, both are related according to
CLblood ¼ QlivCLintKliv
Qliv þ CLintKliv ; ð15Þ
where Kliv denotes the liver tissue-to-blood partition coefficient (e.g., as resulting
from Eq. 14). The hepatic extraction ratio, Ehep, is defined as
Ehep ¼ CLintKliv
Qliv þ CLintKliv ; ð16Þ
with 0 B Ehep \ 1.
Given a PBPK model, the volume of distribution in steady state Vss can be readily
estimated by
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Vss ¼ Vblood þ
X
tis
VtisKtis þ VlivKlivð1  EhepÞ; ð17Þ
where the sum
P
tis is taken over all non-eliminating tissues/organs of the detailed
PBPK model.
Residual error measurements
We compared the predicted concentration for venous plasma based on the
13-compartment PBPK model (CPBPK) and a lumped compartment model (CLumped)
using the following measure of the residual error:
CPBPK  CLumped
 
PBPK
¼
R T
0
jCPBPKðtÞ  CLumpedðtÞj dtR T
0
CPBPKðtÞ dt
; ð18Þ
where T denotes the final simulation time. The denominator of the above measure is
identical to the well-known area under the concentration-time curve AUC0-T, so we
measured the deviation between predictions relative to the AUC0-T as predicted by
the PBPK model.
Simulations and model fitting
We used MATLAB R2009a, version 7.8 for modeling and simulation (ode15s
solver). Model fitting was performed using the MATLAB Optimization Toolbox,
version 4.2, and the predefined function ‘lsqcurvefit’ with default options and the
sum of least squares deviation as the criterion for model discrimination.
Table 1 Organ-specific data
of the human PBPK model
The physiological data are
taken from [6]. We consider the
standard male human with a
body weight of 73 kg and an
cardiac output of 6.5 l/min [22,
23]. The right column shows
the tissue-to-blood partition
coefficients, Ktis (see Eq. 14)
that are predicted based on the
tissue-to-unbound plasma
partition coefficients Kutis
according to [15, 17] for
Lidocaine. BW body weight,
CO cardiac output
Tissue Volume
(l/kg BW)
Blood flow
(fraction of CO)
Ktis
Artery 0.0257 1.00 –
Vein 0.0514 1.00 –
Adipose 0.1196 0.05 1.548
Bone 0.0856 0.05 1.940
Brain 0.0200 0.12 1.871
Gut 0.0171 0.17 3.780
Heart 0.0047 0.04 3.033
Kidney 0.0044 0.19 6.236
Liver 0.0257 0.25 5.923
Lung 0.0076 1.00 4.699
Muscle 0.4000 0.17 2.514
Skin 0.0371 0.05 2.175
Spleen 0.0026 0.02 4.144
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Results
Lumping of whole-body PBPK models
The simulation results of the generic PBPK model for Lidocaine are shown in
Fig. 2. As Lidocaine is typically injected as an antiarrhythmic drug [34], we
considered a 60 min infusion of Lidocaine. Its therapeutic concentrations are within
2–6 mg/l [3], whereas no more than 600 mg should be given in any 12 hour period
[34]. We chose a total dose of 400 mg Lidocaine so that after *10 min a blood
concentration in the therapeutic window is reached (see Fig. 2, vein).
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Fig. 2 Predictions of the 13 compartment whole-body PBPK model (green solid line), and the lumped
4-compartment PK model (black dashed line) following a 60 min infusion of 400 mg of Lidocaine in
human for eight representative organs/tissues. The detailed PBPK model and the lumped model show
excellent agreement. (Color figure online)
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In the sequel, we describe the proposed lumping procedure. The input data were
the concentration-time profiles in the different organs, tissues and other spaces as
predicted by the whole-body PBPK model. In this study, we focussed on the
important class of PBPK models, where all absorption, distribution, metabolism and
excretion processes are non-saturable. We first dealt with perfusion rate-limited
(well-stirred) organ models, while then we extended the lumping to permeability
rate-limited organ models.
Identification of organs and tissues to be lumped together
Figure 3 (top) is the key to understand the new lumping method. It depicts
normalized concentration-time profiles of all 13 compartments of the detailed PBPK
model (for Lidocaine). Each concentration-time profile Ctis(t) was normalized by its
elimination-corrected tissue-to-blood partition coefficient, i.e.
Normalized Concentration ¼ CtisðtÞ
Ktisð1  EtisÞ ; ð19Þ
where for non-eliminating tissues, it is Etis = 0, while for eliminating tissues Etis
denotes the tissue extraction ratio. In our PBPK model for Lidocaine, only the liver
is extracting, in which case Eliv denotes the hepatic extraction ratio.
We identified two distinct phases in Fig. 3 (top): (i) an initial transient phase
resulting from distributional processes; and (ii) a quasi-steady state elimination
phase (approximately after 4 h, Fig. 3). Apparently, the ‘‘kinetic diversity’’ of
concentration-time profiles is much smaller than the potential 13 dimensions of the
PBPK model. We easily identify four different groups of organs and tissue with
almost identical normalized concentration-time profiles: {muscle}, {adipose, bone},
{skin} and {rest = all remaining tissues and organs}. These four groups defined the
lumped compartments of the reduced model for Lidocaine. Since the PBPK model
was assumed to be linear, the grouping does not depend on the administered dose.
A slightly different scaling gave further insight about the elimination phase. In
Fig. 3 (bottom), the concentration-time profiles of all 13 compartments of the
detailed PBPK model were scaled according to Ctis(t)/Ctis(tel), where the time tel has
been chosen to lie safely in the quasi-steady state elimination phase (we choose
tel = 8 h for Lidocaine).
This scaling showed more clearly the differences in the initial distributional
phase and the identical decay in the elimination phase. It can alternatively be
obtained from the first one by including into the scaling factor Ktis some factor SFtis,
such that Ctis(tel) = Ktis SFtis. This additional factor has a physiological interpre-
tation: The normalized concentrations Ctis(t)/Ktis correspond to the venous blood
concentrations leaving the compartments (by definition of the tissue-to-blood
partition coefficient). Figure 3 (top) shows that venous blood concentrations leaving
the compartments are not identical in the elimination phase. Since the liver is
continuously eliminating drug from the blood, there is a net loss of drug from each
compartment as a result of the decreasing concentration in the perfusing blood. This
net loss depends on both, physiological parameters (like blood flows and organ
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volumes), as well as drug-specific parameters, and is determining the additional
factor SFtis.
In summary, we used the normalized concentration-time profiles in Fig. 3 (top)
to identify groups of compartments of the detailed PBPK model that behave
kinetically similar. While we identified the organs to be lumped based on visual
inspection, we also derived an automated procedure to identify organs with similar
kinetics based on linear dependence of the normalized concentration-time profiles
(see Appendix D).
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Fig. 3 Normalized tissue concentrations for Lidocaine based on predictions of the detailed, 13
compartment PBPK model. Top: Normalization of tissue concentrations Ctis based on the tissue-to-blood
partition coefficient Ktis for non-eliminating tissues/organs, Kliv(1 - Ehep) for the liver. Vein and artery
were not scaled. Bottom: Normalization of tissue concentrations Ctis based on the concentration Ctis(tel)
at some time tel associated with the elimination phase (for non-eliminating tissues/organs and
correspondingly for eliminating organs, artery and vein). We chose tel = 8 h in this example. Identical
colors/line styles indicate the proposed grouping of organs according to similar concentration-time
profiles. Data correspond to an 60 min infusion of 400 mg Lidocaine. (Color figure online)
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Lumping condition
In accordance with Fig. 3, we derived the following
Lumping criteria:
C1ðtÞ
K1
¼ C2ðtÞ
K2
¼ Cel
Kelð1  EelÞ ¼ :::; ð20Þ
where C1, C2 refer to non-eliminating compartments and Cel refers to, if any, an
eliminating compartment (with extraction ratio Eel) to be lumped together. For
Lidocaine, the only eliminating compartment was the liver. The lumping criteria
allowed us to derive parameters and differential equations for the lumped
compartment.
It is worth noticing that the above lumping criteria does not make any
assumptions on whether organs or compartments are in series or parallel, as the
previous lumping method by Nestorov et al. [11] did. We defined the central
compartment (‘cen’) as the lumped compartment that contains the vein; and we
denote the lumped compartment that contains the liver ‘liv’ as ‘Liv’.
Parameter values for the lumped compartment
The volume of a lumped compartment VL was defined as
VL ¼
X
tis
Vtis; ð21Þ
where the sum is taken over all original tissues/organs that were lumped. We
defined the concentration CL of the lumped compartment based on the conservation
of mass as
CLðtÞ ¼ 1
VL
X
tis
VtisCtisðtÞ: ð22Þ
Exploiting the lumping criteria, and dividing the above equation by the blood
concentration Cblood yielded the defining equation for the tissue-to-blood partition
coefficient KL for non-eliminating lumped compartments:
KL ¼ 1
VL
X
tis
VtisKtis; ð23Þ
and for eliminating lumped compartments:
KLiv ¼ 1
VLiv
X
tis 6¼liv
VtisKtis þ VlivKlivð1  EhepÞ
 !
; ð24Þ
where we formally defined Kven = Kart = 1. For any lumped compartment except
the central compartment, we defined the lumped blood flow QL by
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QL ¼
X
tis
Qtis; ð25Þ
where the sum
P
tis is taken over all original compartments that were lumped
together into ‘L’. The blood flow Qcen of the central compartment was defined as
Qcen ¼
X
L
QL; ð26Þ
where the sum is taken over all lumped compartments that have an inflow into the
central compartment.
Differential equations for the lumped compartments
We derived the equations for the rate of change of the concentration in the lumped
compartment based on Eq. 22. The derivation is given in Appendix B. For each
lumped compartment except the central compartment, it is
VL
d
dt
CL ¼ QL Ccen
Kcen
 CL
KL
 
: ð27Þ
For the central compartment, we distinguished two situations. If the liver is part of
the central compartment, then it is
Vcen
d
dt
Ccen ¼ Qcen Cin  Ccen
Kcen
 
 CLblood Ccen
Kcen
þ riv;poðF;bioÞ; ð28Þ
where the inflowing concentration was given by
Cin ¼ 1
Qcen
X
L
QL
CL
KL
; ð29Þ
and the sum is taken over all lumped compartments except the central compartment.
If the liver is not part of the central compartment, it is
Vcen
d
dt
Ccen ¼ Qcen Cin  Ccen
Kcen
 
 CLblood CLiv
KLiv
þ riv; ð30Þ
while for the ’Liv’ compartment it is
VLiv
d
dt
CLiv ¼ QLiv Ccen
Kcen
 CLiv
KLiv
 
þ rpoðFFGÞ: ð31Þ
The incoming concentration Cin in Eq. 30 is defined as in Eq. 29. Note the
difference in the dosing term; while we used Fbio = (1 - Ehep)FFG in the dosing
term of Eq. 28, we used FFG in the dosing term of Eq. 31.
We remark that Eq. 28 is actually a special case of Eq. 30. In the latter case, the
term CLiv/KLiv corresponds to the concentration of the blood leaving the lumped
compartment that contains the liver, which is identical to the blood concentration of
the central compartment in the case, where the liver is lumped with the blood
compartment according to Eqs. 32 and 35.
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Prediction of individual tissue concentrations
Based on the lumping criteria, we could easily regain individual concentrations of
the original compartments that were lumped together. This process amounts to
reversing the lumping procedure. Based on the concentration CL and partition
coefficient KL of the lumped compartment we determined the original tissue
concentration by (see Appendix A for details)
Ctis ¼ Ktis  CL
KL
ð32Þ
CvbL ¼ CL
KL
ð33Þ
Cliv ¼ Klivð1  EhepÞ  CL
KL
; ð34Þ
where CvbL denotes the venous concentration leaving the lumped compartment. If
the liver is part of the central compartment, then CL/KL = Ccen/Kcen in Eq. 34,
otherwise it is CL/KL = CLiv/KLiv. For the venous blood, we have
Cven ¼ Ccen
Kcen
: ð35Þ
It is important to notice that the scaled concentration Ccen/Kcen rather then Ccen itself
is the venous blood concentration that is to be compared to experimental data. The
blood concentration can be related to the plasma concentration Cplasma = Cven/B:P
using the blood-to-plasma partition coefficient B:P.
Step-by-step lumping procedure
In summary, the proposed lumping scheme comprised the following steps:
1. Simulate the whole-body PBPK model to predict the concentrations Ctis(t) in all
organs and tissues.
2. Plot the normalized concentrations according to Eq. 19 and identify the groups
of organs/tissues with similar normalized concentration-time profiles.
3. For each group of organs/tissues L, determine the lumped volume, blood flow
and partition coefficient according to Eqs. 21–26.
4. Use Eqs. 27–29 or Eqs. 29–31 to simulate the lumped model and to predict the
lumped concentrations CL for all groups of organs/tissues.
5. Use Eqs. 32–35 to predict the original tissue concentration Ctis from CL for each
organ/tissue group.
We have derived the lumped parameters and ODEs under the lumping condition. In
practice, we require to hold it only approximately, i.e., we require only that the
normalized concentrations are (very) close to each other, as it is also done in the
existing lumping approaches.
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Volume of distribution Vss
The volume of distribution at steady state Vss is defined as
Vss ¼ Ass;tot
Css;ven
; ð36Þ
where Ass,tot denotes the total amount of drug in the body and Css,ven the venous
blood concentration in steady state. Noting that the tissue-to-blood partition coef-
ficients Ktis are the ratios of the tissue and blood concentrations in steady state, and
exploiting Eqs. 21, 22 and 24, we obtained
Vss ¼
X
L
VLKL ð37Þ
¼ Vven þ Vart þ
X
tis
VtisKtis þ Vlivð1  EhepÞKliv; ð38Þ
where the first sum is taken over all compartments of the lumped model, and the
second sum is taken over all non-eliminating tissues/organs of the detailed PBPK
model. Hence, our lumping methods preserves the volume of distribution Vss, which
is identical to the volume of distribution of the original PBPK model (see Eq. 17).
Importantly, preservation of Vss does not depend on whether the eliminating liver
organ is part of the central or any peripheral lumped compartment.
Relation to classical one- and two-compartment models
We compared our mechanistically lumped models with classical PK compartment
models to obtain a potential mechanistic interpretation of classical models. We
exemplified the relation for classical 1-compartment and 2-compartment models.
We set radmin ¼ riv;poðFbioÞ.
The mechanistic 1-compartment model was obtained by applying the lumping
procedure to lump all compartments of the PBPK model into a single lumped
compartment. The rate of change for the lumped concentration Ccen of the central
compartment is given by
Vcen
d
dt
Ccen ¼ radmin  CLblood Ccen
Kcen
ð39Þ
where Vcen denotes the total volume of all organs/tissues (defined as in Eq. 21), and
Kcen denotes the tissue-to-blood partition coefficient for the central compartment
(defined as in Eq. 24). The classical 1-compartment model was defined as
Vss
d
dt
C1 ¼ radmin  CL  C1; ð40Þ
where Vss denotes the volume of distribution, C1 the total tissue concentration and
CL the total body clearance. Figure 4a illustrates the mechanistic as well as classical
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1-compartment model, and shows the relationship between the model parameters
(middle column).
The mechanistic 2-compartment model was derived under the assumption that
the liver is part of the central compartment (alternative assignments are possible).
The rate of change of the concentrations in the central and peripheral compartment
Ccen and Cp with volumes Vcen and Vp and partition coefficients Kcen and Kp,
respectively, were given by
Vcen
d
dt
Ccen ¼ Q Cp
Kp
 Ccen
Kcen
 
 CLblood Ccen
Kcen
þ radmin ð41Þ
Vp
d
dt
Cp ¼ Q Ccen
Kcen
 Cp
Kp
 
ð42Þ
Analogously, the classical 2-compartment model was specified in terms of the
central and peripheral concentrations C1 and C2,
V1
d
dt
C1 ¼ q  C2  q  C1  CL  C1 þ radmin ð43Þ
V2
d
dt
C2 ¼ q  C1  q  C2; ð44Þ
where V1, V2 denote the volumes of the central and peripheral compartment,
respectively, q denotes the inter-compartmental transfer flow, and CL the hepatic
(a)
(b)
Fig. 4 Relationship between mechanistic (left) and classical (right) 1 and 2-compartment models. The
equations in the middle describe the relationship between the model parameters. The central compartment
is by definition the lumped compartment containing the venous blood
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blood clearance. Figure 4(b) illustrates the mechanistic and classical 2-compartment
models and the relationship between the model parameters.
Lumping of a 13 compartment whole-body PBPK model of perfusion rate-
limited organs
We illustrated the proposed lumping approach for our model compound Lidocaine.
The concentration-time profiles were clustered into four groups: {muscle},
{adipose, bone}, {skin}, and the central compartment containing all remaining
organs {vein, artery, lung, brain, heart, kidney, gut, spleen, liver}. We used the
different steps outlined in ’Step-by-step lumping procedure’ to derive the
corresponding set of ODEs.
The predicted concentration-time profiles for the different physiological com-
partments based on the lumped 4-compartment PK model and Eqs. 32–35 are shown
in Fig. 2. All predicted organ/tissue concentrations were in excellent agreement
with the predictions of the detailed 13-compartment PBPK model.
Lumping of a 18 compartment whole-body PBPK model of perfusion
and permeability rate-limited organs
We used a detailed whole-body PBPK model for a homologous series of
barbiturates in rats [11, 35] to illustrate application of our lumping method in the
case, where some of the organs show permeability-limited distribution, while the
remaining organs are perfusion rate-limited. The PBPK model comprised 18
organs, tissues and vascular compartments and is depicted schematically in Fig. 5.
For all organs/tissues but brain and testes, a perfusion rate-limited, i.e, well-
stirred, tissue model was assumed, whereas for brain and testes, tissue distribution
was assumed to be permeability rate-limited. In addition to the liver metabolism,
drug clearance of the unbound drug in plasma by the kidneys was taken into
account. The required species- as well as drug-specific data were taken from [35].
For the tissue-to-unbound plasma partition coefficients, we used the optimized
values reported in [35]. Simulation results for barbiturate C3 are shown in Fig. 7
(green solid line).
Figure 6 shows the normalized organ and tissue concentrations for all 18
compartments, where we included both, the vascular (vas) and the tissue (tis)
concentration-time profiles for the two permeability rate-limited tissues testes and
brain (as for plasma, we set the partition coefficients for the vascular parts of brain
and testes to 1). We identified four sets of compartments to be lumped: {gut, spleen,
pancreas, liver}, {skin, bone, brain(tis)}, {muscle, adipose, testes(tis)}, in addition
to the central compartment {lung, artery, vein, kidneys, heart, stomach, brain(vas),
testes(vas)}.
Our lumping approach naturally extends to permeability rate-limited organ
models, as described in detail in Appendix C. For lumping of a permeability rate-
limited organ, we derived the following
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Fig. 5 Organ and tissue
topology of the detailed, 18
compartment whole-body PBPK
model for a barbiturate.
Distribution in testes and brain
was assumed to be permeability-
rate limited, while it was
assumed to be perfusion-rate
limited for all remaining tissues
and organs. The required
species- as well as drug-specific
data are given in [35]
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Fig. 6 Normalized tissue concentration for the barbiturate C3 based on predictions of an 18-
compartment whole-body PBPK model [35]. Normalization based on the tissue-to-blood partition
coefficient Ktis for non-eliminating tissues/organs, Ktis(1 - Etis) for the two eliminating organs liver and
kidney, and Ctis(t) for the vein and the artery. Identical colors/line styles indicate the proposed lumping of
organs according to similar concentration-time profiles. (Color figure online)
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Permeability rate-limited criteria:
Qtis
PStis þ Qtis [
PStis
PStis þ Qtis : ð45Þ
This criteria ensures that permeability rather than perfusion is the rate-limiting step
of tissue distribution. For details see Eq. 85. If this condition would be violated, then
the model could reasonably be considered as either mixed perfusion and
permeability rate-limited, or as solely perfusion rate-limited (depending on the
actual values). In the former case, the interplay between vascular and tissue part is
expected to be critical, such that the compartment should be left un-lumped. In the
latter case, the organ model could be changed to the simpler perfusion rate-limited
model. For the barbiturate C3, the permeability rate-limited criteria was satisfied for
both, brain and testes.
Under the permeability rate-limited criteria, the vascular part of a permeability
rate-limited organ can be lumped together with the venous blood, while the tissue
parts are lumped based on (see Appendix Eq. 87)
Vtis
d
dt
Ctis ¼ PStis  Qtis
PStis þ Qtis  Cblood 
Ctis
Ktis
 
: ð46Þ
Hence, when lumping the tissue part of a permeability-limited tissue model, the
term
PStis  Qtis
PStis þ Qtis ð47Þ
takes the role of the tissue blood flow Qtis for perfusion rate-limited models
(cf. Eq. 25).
Predictions of the lumped 4-compartment model are shown in Fig. 7 (dashed
black line) for different organs and tissues. For almost all of the organs/tissues, the
predictions were in excellent agreement with the detailed 18 compartment model.
For muscle and adipose, the initial concentrations were slightly overestimated. This
could be improved by considering adipose as a separate compartment in the lumped
model, which would then comprise 5 compartments.
Characteristic features of mechanistically lumped PK models
for moderate-to-strong bases, weak bases, and acids
A major determinant of drug disposition is tissue distribution. We used a recent
approach to a priori predict tissue-to-unbound plasma partition coefficients [15–18]
to parameterize the 13-compartment whole-body PBPK model for a number of
different drugs. These in silico approaches regard the tissue as comprising an
interstitial and an intra-cellular space. The unbound drug is possibly ionized in the
interstitial and intra-cellular space and the neutral species can cross membranes by
passive diffusion. In the intra-cellular space, the neutral species may distribute into
neutral lipids and neutral phospholipids. In addition, a drug may bind to further
tissue constituents. For moderate-to-strong bases, it is assumed that binding to
acidic phospholipids is a major determinant of intra-cellular distribution. For weak
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bases, neutrals and acids, binding in the interstitial space is an important
determinant. It is assumed that weak bases and acids bind to albumin, while
neutrals are assumed to bind to lipoproteins [15, 17, 36].
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Fig. 7 Comparison of predictions of an 18 compartment whole-body PBPK model including
permeability rate-limited compartments for brain and testes (green solid line, ‘PS-limited’) and our
lumped 4-compartment PK model (black dashed line, ‘4-cmt lumped’) following a 25 lmol i.v. bolus
dose of a barbiturate C3 [35] in the rat for representative organs/tissues. The permeability rate-limited
PBPK model and the lumped 4-compartment PK model show very good agreement for almost all
compartments (see liver and testes for two out of 14). Adipose and muscle are slightly overestimated
initially. For venous blood, predictions for an artificially transformed whole-body PBPK model, where the
compartments brain and tested were converted to the perfusion rate-limited model, are shown (red dot-
dashed line, ‘Q-limited’). This model was the starting point of existing lumping methods, since they were
not able to lump permeability rate-limited models. (Color figure online)
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We investigated, whether mechanistically lumped PK models exhibit character-
istic features based on the alkalinity/acidity of the drug. We considered 25 drugs
with different alkalinity/acidity. See Table 3 for the drug-specific parameters. The
compounds were chosen from [24, 25, 27]. We restricted our analysis to those
compounds for which all parameters for the PBPK modelling were available in
literature. The availability of the blood-to-plasma ratio B:P was the limiting factor
restricting the choice of drugs.
For each drug, we predicted the concentration-time profiles based on the generic
13-compartment whole-body PBPK model shown in Fig. 1 for a 60 min i.v.
infusion. Administration by infusion was chosen, since it did not require any
additional parameter values as, e.g., the absorption rate constant for oral absorption.
We determined the number of compartments for a mechanistically lumped PK
compartment model based on the algorithm outlined in Appendix D. The predicted
number of compartments for the different compound classes moderate-to-strong
bases, weak bases and acids are shown in Fig. 8.
For all drugs except Midazolam and Thiopental, a maximal 4-compartment
lumped PK model was sufficient to predict the drug PK in all 13 different
physiological tissues/organs. If a lumped model comprised more than a single
compartment, then adipose, bone, muscle and skin were typically not part of the
central compartment (see Fig. 9). From these four tissues/organs, skin usually
showed closest similarity to the central compartment.
In Table 2, physiological and anatomical data for adipose, bone, muscle and skin
are listed for an average human. Their important role in tissue distribution is due to
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Fig. 8 Predicted number of compartments for the mechanistically lumped PK model based on
concentration-time profiles generated by the 13-compartment whole-body PBPK models. The colors
indicate the categorization of drugs as follows: moderate-to-strong bases (left, green), weak bases
(middle, blue) and acids (right, red). (Color figure online)
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their distinct characteristics. The four organs make the largest fraction of the total
body volume with muscle being by far the largest tissue. At the same time, their blood
flows are amongst the lowest. Regarding important tissue constituents influencing
tissue distribution, the four tissues/organs typically show distinct characteristics at
the extremes: adipose has lowest tissue water, high neutral lipids and low
phospholipids; bone has lowest phospholipids, muscle and skin have high tissue
water. These characteristics make them key tissues/organs in drug distribution.
For a number of acidic drugs, the predicted lumped compartment contained only
a single compartment, while for other acids the number of compartments was 2, 3 or
5. We identified the fraction unbound in plasma fup as the discriminating parameter:
For acids with a low fup (in our examples fup B 0.1) a mechanistically
ve lu ar ki gu sp li ht br sk bo mu ad
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Fig. 9 Predicted assignment of organs, tissues and other spaces of the whole-body PBPK model to the
lumped compartments of the mechanistically lumped model for the same 25 compounds as in Fig. 8. The
central compartment is represented by x, potential additional peripheral compartments are represented by
circle, square, diamond etc. The number of different symbols for a given compound corresponds to the
number of compartments in the mechanistically lumped model
Table 2 Physiological and anatomical data for adipose, bone, muscle, skin and remaining tissues [6, 24]
adipose bone muscle skin remaining organs
Volume 0.12 0.086 0.40 0.037 0.0026–0.026
Blood flows 0.05 0.05 0.17 0.05 0.02–1.0
Tissue water 0.15 0.44 0.76 0.62 0.72–0.81
Neutral lipids 0.79 0.074 0.024 0.028 0.003–0.051
Phospholipids 0.002 0.001 0.007 0.011 0.009–0.057
Volume: fraction of total body weight (BW); blood flow: fraction of cardiac output (co); tissue water,
neutral lipids, phospholipds: fraction of total tissue volume (Vtis). The column ’remaining organs’ lists the
minimum and maximum value amongst all remaining organs considered in the whole-body PBPK model
depicted in Fig. 1
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1-compartment PK model was sufficient, while for acids with a moderate-to-high
fup (in our examples fup C 0.18) two or more compartments were predicted.
For moderate-to-strong bases, muscle, bone, adipose, and skin were part of
lumped compartments in different combinations. Mostly, muscle and skin formed
separate compartments, if skin was not part of the central compartment (see Fig. 9).
Lumping and tissue distribution half-life
Based on the well-stirred tissue model, we may associate with each tissue a
distributional half-life: Rearranging Eq. 1 yielded
d
dt
Ctis ¼ QtisCin
Vtis
 Qtis
VtisKtis
 Ctis: ð48Þ
The pre-factor of the second summand can be interpreted as a distribution rate
constant
ktis ¼ Qtis
VtisKtis
ð49Þ
associated with the tissue, where Vtis  Ktis can be understood as the volume of
distribution associated with the tissue. For eliminating organs, Ktis was corrected by
the tissue extraction ratio resulting in Ktis(1 - Etis). Based on ktis we may charac-
terize the kinetics of tissue distribution by the
Tissue distribution half-life ¼ lnð2Þ
ktis
: ð50Þ
This half life corresponds to the situation, in which the inflowing drug concentration
Cin is assumed to be constant. Tissue distribution is the slower the larger the product
VtisKtis(1 - Etis) or the smaller the blood flow Qtis perfusing the tissue or organ.
In Fig. 10, the tissue distribution half-lives for the compounds listed in Table 3
are shown. Organs/tissues that were clustered together by our lumping method are
marked with the same marker (cross, circle, square, etc). Noticeably, the tissue
distribution half-life for different lumped compartments do not overlap. A decision
on how to lump organs based on their tissue distribution half-life is possible—and
the lumping criteria of existing lumping methods [11, 13]—but much harder.
Minimal lumped models as the link between PBPK and classical compartment
models
The aim of the mechanistic lumping approach was to predict the concentration-time
profiles of all organs and tissues from the lumped model. If only plasma or blood
data are available, as is typically the case in clinical trials, the question arises
whether it is possible to derive lumped PK compartment models that allow us to
predict the venous blood concentration with as few compartments as possible. These
models were termed ’minimal lumped models’. We used the predicted venous blood
concentration by the 13-compartment whole-body PBPK model following a 400 mg
i.v. infusion (60 min) of Lidocaine to illustrate minimal lumping.
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The minimal lumped model was determined on the basis of the mechanistically
lumped model by further lumping together additional compartments. We started
with a tentative minimal model comprising a {adipose, bone, muscle} compartment
in addition to the central compartment and then moving further tissues into the
central compartment. Predictions were checked against the detailed PBPK model
predictions for the venous compartment.
Figure 11 shows the predicted blood concentrations of the mechanistically
lumped 4-compartment PK model and a minimal lumped model in comparison to
the prediction of the whole-body PBPK model. The minimal lumped model
comprised a lumped compartment containing {adipose, bone, muscle} in addition to
the central compartment. The parameter values of Vcen, Vp, Q and CLblood are given
in Table 4 (left). We inferred from Fig. 11 that predictions of the detailed
PBPK model, the mechanistically lumped 4-compartment model, and the minimal
2-compartment model were almost identical for venous blood.
We further analyzed whether the minimal 2-compartment model could serve as a
structural model to fit venous blood data generated by the whole-body PBPK model
(considered as a surrogate for experimental data). The estimated parameters V1, V2,
q and CL of the classical 2-compartment model are given in Table 4 (right), and the
predicted concentration-time profile for venous plasma is shown in Fig. 11 (2-cmt
emp. fit).
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Fig. 10 Tissue distribution half-life for the same 25 compounds of Fig. 8 and all organs, tissues and
other space of the generic 13-compartment PBPK model. For each compound, the 13 markers represent
the 13 organs and tissues of the generic PBPK model. Identical symbols represent organs and tissues that
were lumped together in our mechanistically lumped PK model. As in Fig. 9, the central compartment is
represented by x, potential additional peripheral compartments are represented by circle, square, diamond
etc. Artery (at 0.29 min) and vein (at 0.58 min) are clearly visible for all compounds, since these are the
only two spaces whose half life does only depend on volume and blood flow, but not on a drug-specific
partition coefficient
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Based on the relations given in Fig. 4, we determined the parameter values of V1,
V2, q and CL from the minimal lumped model, see Table 4 (middle) for comparison.
All parameters show excellent agreement.
We next studied minimal lumped models for the 25 model compounds in
Table 3, see Fig. 12. Also here, the distinct role of the adipose, muscle and bone
compartments was present. We used the residual error measure k  kPBPK defined in
Eq. 18 to quantify the difference between the venous plasma concentration
predicted by the PBPK model and a potential minimal model, and regarded the
minimal model as adequate, if the residual error was below e = 0.09 (a common
value for all drugs allowed for unbiased comparison).
Table 3 Physicochemical and pharmacokinetic data of 25 diverse compounds
Drug pKa log Pow fu
p B:P CLblood
(ml/min/kg)
Moderate-to-strong bases
Amitriptyline 9.40a 4.90a 0.056a 0.86a 12.00b
Caffeine 10.40a - 0.09a 0.700a 1.04a 1.40c
Desipramine 10.32a 4.90a 0.190a 0.96a 12.00b
Diltiazem 7.70a 2.67a 0.200a 1.03a 12.00b
Diphenhydramine 8.98a 3.31a 0.089a 0.80a 9.50b
Imipramine 9.50a 4.80a 0.130a 1.12a 12.00b
Lidocaine 8.01a 2.26a 0.296a 0.84a 15.00c
Metoprolol 9.70a 2.15a 0.900a 1.14a 12.15c
Pindolol 8.80a 1.75a 0.410a 0.81a 4.20c
Sildefanil 7.60a 2.75a 0.040a 0.62a 6.00c
Theophylline 8.71a 0.26a 0.600a 0.83a 0.65c
Weak bases
Alprazolam 2.40d 2.09d 0.320b 0.78b 0.76b
Diazepam 3.38d 2.84d 0.013b 0.71b 0.60b
Flunitrazepam 1.80d 2.06d 0.250e 1.20e 9.8 (ml/min)e
Midazolam 6.01d 3.15d 0.050b 0.53b 8.70b
Triazolam 2.00d 2.42d 0.100b 0.62b 4.70b
Acids
Amobarbital 7.90d 1.89d 0.390b 1.50b 0.35b
Diclofenac 4.15f 3.90f 0.005b 0.55b 7.60b
Hexobarbital 8.29d 1.74d 0.530b 1.00b 3.60b
Ibuprofen 4.70d 4.06d 0.010b 0.55b 1.50b
Methohexital 8.30d 1.72d 0.270b 0.70b 16.00b
Thiopental 7.53d 2.93d 0.180d 0.88h 2.02i
Tolbutamide 5.29d 2.39d 0.040b 0.55b 0.36b
Valproate 4.60d 2.76d 0.099d 0.55j 0.11j
Warfarin 5.08g 3.00g 0.010b 0.55b 0.081b
a [24], b [25], c [26], d [27], e [28], f [29], g [30], h [31], i [32], j [33]
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For Midazolam and Thiopental, the minimal lumped model comprised 3
compartments. For those compounds where the mechanistically lumped model
already comprised only 1- or 2-compartments, this number could not be further
reduced. For all other compounds, a minimal 2-compartment model comprising an
{adipose, muscle, bone} compartment in addition to the central compartment
resulted in excellent predictions for venous plasma when compared to those
predicted by the whole-body PBPK model.
Alternative routes of administration
In this section we analyzed the impact of the route of administration on
mechanistically lumped and minimal lumped models.
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Fig. 11 Comparison of the 13-compartment whole-body PBPK model for Lidocaine to a mechanistically
lumped 4-compartment model and a minimal lumped 2-compartment model for venous blood. In
addition, the predictions of an empirically fitted classical 2-compartment model are shown. All models
show excellent agreement
Table 4 Comparison of parameters of the fitted classical 2-compartment model (right) and the minimal
lumped model (left and middle)
Minimal model Determination of empiric parameters based on:
Minimal parameters Empirical fitting
Vcen 14.33 V1 29.7 21.5
Vp 44.18 V2 99.1 99.8
Q 1.91 q 1.91 1.85
Kcen 2.07 CL 1.10 1.09
Kp 2.24
Parameters of the minimal lumped model (left) were transformed into corresponding parameters of the
classical compartment model as in Fig. 4 (middle)
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Per oral administration
We used the detailed whole-body PBPK model to predict a single p.o. adminis-
tration of 400 mg Lidocaine. We used FFG = 1, and due to the absence of a human
value the canine first order absorption rate constant k = 0.018 min-1 [37]. After
oral administration of Lidocaine in human, maximum plasma concentrations have
been observed between 30 and 45 min [38], which is in accordance with the chosen
absorption rate constant.
Figure 13 (top) shows the normalized concentrations Ctis/(Ktis(1 - Etis)). The
situation was almost identical to the situation of an i.v. infusion (cf. Fig. 3), except
that the normalized liver concentration showed a different ‘shape’. This different
shape is the result of the influx of drug through the portal vein. As a consequence,
the number of compartments of the mechanistically lumped PK model increases by
one: {muscle}, {adipose, bone}, {skin}, {liver} and {rest = all remaining tissues
and organs}.
An increase in the number of compartments of the mechanistically lumped model
does not necessarily result in an increased number of compartments of the minimal
lumped model. Figure 13 (bottom) shows the venous plasma concentration as
predicted by the 13-compartment whole-body PBPK model, the mechanistically
lumped 5-compartment model, and a minimal lumped 2-compartment model
comprising a {muscle, adipose, bone} compartment in addition to the central
compartment. The predictions were in excellent agreement. Hence, although the p.o.
administration increases the number of compartments of the mechanistically lumped
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Fig. 12 Predicted number of compartments for the minimal lumped PK model based on concentration-
time profiles generated by the 13-compartment whole-body PBPK models. The colors indicate the
categorization of drugs as follows: moderate-to-strong bases (left, green), weak bases (middle, blue) and
acids (right, red). (Color figure online)
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compartment, it did not increase the number of compartments of the minimal
lumped model.
Intravenous bolus administration
We next analyzed an i.v. bolus administration of 400 mg Lidocaine. Figure 14 (top)
shows the normalized concentrations Ctis/(Ktis(1 - Etis)). The number of distinct
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Fig. 13 Normalized tissue concentrations for Lidocaine based on predictions of the detailed, 13
compartment PBPK model for a p.o. administration. Top: Normalization of tissue concentrations Ctis
based on the tissue-to-blood partition coefficient Ktis for non-eliminating tissues/organs, Kliv(1 - Ehep)
for the liver. Vein and artery were not scaled. Bottom: Comparison of the 13-compartment whole-body
PBPK model for Lidocaine to a mechanistically lumped 5-compartment model and a minimal lumped
2-compartment model for venous blood for p.o. administration. Data correspond to a single dose of
400 mg Lidocaine and show excellent agreement
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concentration-time profiles in comparison to the i.v. infusion (cf. Fig. 3) is again
increased by one: {muscle}, {adipose, bone}, {skin}, {vein, lung, artery} and
{rest = all remaining tissues and organs}. The mechanistically lumped model
yielded excellent predictions for all organs from 10 min on. If concentration-time
profiles below 10 min have to be predicted, then the number of compartments in the
mechanistically lumped model would have to be increased to account for the very
first distributional phase.
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Fig. 14 Normalized tissue concentrations for Lidocaine based on predictions of the detailed,
13 compartment PBPK model for an i.v. bolus administration. Top: Normalization of tissue
concentrations Ctis based on the tissue-to-blood partition coefficient Ktis for non-eliminating tissues/
organs, Kliv(1 - Ehep) for the liver. Vein and artery were not scaled. Bottom: Comparison of the
13-compartment whole-body PBPK model for Lidocaine to a mechanistically lumped 5-compartment
model and a minimal lumped 2-compartment model for venous blood for an i.v. bolus administration.
Data correspond to a single dose of 400 mg Lidocaine and show excellent agreement
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Figure 14 (bottom) shows the venous plasma concentration as predicted by the
13-compartment whole-body PBPK model, the mechanistically lumped 5-compart-
ment model, and a minimal lumped 2-compartment model comprising a {muscle,
adipose, bone} compartment in addition to the central compartment. Again, all
predictions are in excellent agreement, and the number of compartments of the
minimal lumped model was the same as for an i.v. bolus and an i.v. infusion
administration.
Discussion
In this study we present a novel lumping method for the reduction of whole-body
physiologically-based pharmacokinetic models. We used the proposed method to
translate knowledge present in a 13- and 18-compartment PBPK model into
mechanistically lumped 4-compartment and minimal 2-compartment models. The
proposed method has several advantageous features: (i) there is no restriction on
how organs and tissues can be lumped together; (ii) it is possible to lump perfusion
rate-limited as well as permeability rate-limited compartment models; (iii)
concentrations of the original compartments can be predicted based on the
concentrations of the lumped model; and (iv) the lumping conditions have a
physiological interpretation and are easily visualized. These are significant
advancements over existing lumping methods [11–14].
Nestorov et al. [11] were the first to derive standard lumping principles for PBPK
models. Their lumping principles are based on four conditions: (i) only organs can
be lumped together that are either in parallel or in series (referring to the tissue
topology in Fig. 1); (ii) permeability rate-limited models have to be approximated
by perfusion rate-limited models as a pre-processing step; (iii) vein, lung and artery
are either lumped together or left separate; and (iv) lumping of tissues is based on
similar or small time constants. For non-eliminating tissues, this time constant is
defined as
Ttis ¼ Vtis  Ktis
Qtis
; ð51Þ
while for eliminating organs it is
Ttis ¼ Vtis  Ktis
Qtis þ fubloodCLint ; ð52Þ
where Vtis, Qtis and Ktis refer to the tissue volume, the tissue blood flow and the
tissue-to-blood partition coefficient, respectively; and fublood and CLint denote
the fraction unbound in blood and the intrinsic clearance, respectively. Thus, given
the topology in Fig. 1, the smallest lumped model consistent with the above
conditions (i)-(iii) has at least four lumped compartments: {vein, lung, artery},
{spleen, gut}, {liver}, {all other compartments}. While their equations for the
lumped volume, blood flow and partition coefficient are identical to our Eqs. 21,
25 and 23, it is the lumping criterium (and thereon build derivations) that
distinguishes our approach from the existing approaches. The herein proposed
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lumping criterium, e.g., allows a justified application of lumping, where existing
lumping criteria fail. As a results, we can easily justify the reduction of a 13
dimensional whole-body PBPK model to a single lumped compartment.
The detailed whole-body PBPK model for barbiturates was used by Nestorov
et al. [11] to demonstrate their lumping approach. As an pre-processing step,
however, the permeability rate-limited tissue distribution model for brain and testes
had to be transformed into a perfusion-rate limited model [11]. This reduced the
number of compartments to 16, eliminating the two vascular spaces of brain and
testes. The simulation results of the artificially transformed PBPK model are shown
in Fig. 7(a) (dot-dashed black line, ‘Q-limited’). The differences of the predictions
between the artificially transformed 16-compartment PBPK model and the original
18-compartment PBPK model are much larger than the difference between the
predictions of our lumped 4-compartment model and the original PBPK model.
As in our approach, Nestorov et al. [11] lump together tissues with similar
kinetics. Their measure of similarity is based on the time constant Ttis (Eqs. 51–52).
Some rule of thumb on how similar the time constants Ttis have to be is given in
[11, p. 32–33]. The time constant is related to the tissue distribution half-life by
(cf. Eq. 50)
Tissue distribution half-life ¼ lnð2Þ  Ttis: ð53Þ
Given a list of time constants (see Fig. 10 for a variety of compounds), it can be
very difficult to decide which compartments to lump. Moreover, the time-constants
are independent of any administration details and as such cannot predict different
structures of lumped models for different administrations/dosing schemes. In our
approach, the lumping condition is based on the transient feature of tissue
distribution as well as on the elimination phase after distribution reached quasi-
steady state.
The lumping method in [11, 13] does not relate the predictions of the lumped
model back to predictions of the organs and tissues of the original whole-body
PBPK model. Instead, for comparison with the predictions of the lumped model, the
whole-body PBPK model predictions need to be lumped. The same applies to a
comparison with experimental data. If experimental data were only available for
one, but not all of the original compartments that comprise a lumped compartment,
such an approach would not be applicable. As a consequence, Brochot et al. [12]
introduced a constraint lumping approach, where some of original variables are left
unlumped. While this solves the above mentioned problem, it increases the number
of compartments of the lumped model. With our proposed lumping approach both
aims, a small number of compartments of the lumped model as well as the
possibility to predict original organ and tissue concentration-time profiles, can be
achieved at the same time.
If we were only interested in predictions of the venous blood concentration (as
part of the central compartment), then a further reduction is possible. For our model
compound Lidocaine, we were able to further reduce the lumped 4-compartment
model to a minimal lumped 2-compartment model. A further reduction to one
compartment did seriously compromise the predictions for the central compartment,
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as one would expect due to the bi-exponential characteristics of the concentration-
time profiles.
Analyzing minimal models for a variety of compounds revealed that a minimal
2-compartment model comprising an {adipose, bone, muscle} compartment in
addition to the central compartment (containing all remaining tissues) was almost
always as good in predicting the venous blood concentration as the detailed PBPK
model. This highlights and confirms the importance of adipose, bone and muscle
tissue for drug distribution, which is due to their size and often distinct
characteristics compared to the remaining organs/tissues (cf. also Table 2). A more
thorough analysis about how to more systematically derive a minimal lumped model
from a mechanistically lumped model is work in progress.
The presented analysis based on 25 compounds is a first step towards a more
comprehensive understanding of minimal lumped compartment models. The
limiting factor for the number of compounds considered is the availability of the
blood-to-plasma ratio B:P. From the point of in silico modeling and simulation, this
parameter is an important datum. While it is nowadays by default measured in the
drug discovery phase, it seems rarely be reported in drug data bases.
An important part of classical modelling is to specify the structure of the classical
compartment model. This includes specification of the number of compartments, its
connections, whether processes are linear or non-linear etc. Another important
question is whether elimination takes place in the central or in the peripheral
compartment. This might not only impact convergence of the estimation process,
but also influence pharmacokinetic characteristics like, e.g., the volume of
distribution [39, 40]. Commonly, the ’elimination at the point of observation’
assumption is made, while a compartmental model with peripheral elimination
might give rise to a larger volume of distribution [40].
We observed that for all compounds analyzed in this study, the liver was part of
the central compartment, an observation in favor of the ‘elimination at the point of
observation’ assumption.
A minimal lumped model derived from a whole-body PBPK model evaluated
against pre-clinical and early clinical data can be interpreted as extrapolating the
current knowledge about the drug PK into the next phase. At the same time, a
classical compartment model, e.g., developed as a structural model in population
analysis of clinical trials, based on new experimental data might be interpreted as
representing the minimal description of this new information in terms of a PK
model. A comparison of both models, therefore, offers the possibility to compare
the expectations based on translating previous insights and knowledge with the
information content of new clinical data in form of the classical model. This is a
consistency check of the new data against previous knowledge. In addition, since
the parameters of the classical model have to be estimated based on the
experimental data, the parameters of our minimal lumped compartment model
can be used as initial values in the estimation process, addressing the critical
question of how to chose initial conditions in the parameter estimation process.
Our proposed lumping method in its current form applies to the important class
of linear PK models. Extension to include non-linear behavior seems possible.
Saturable metabolism is likely to be includable based on a non-linear extraction
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ratio. Incorporation of further non-linearities might be more difficult, and results
might then become dose dependent. A more thorough analysis of lumping including
non-linearities has to be left for the future.
Applying our lumping method to a diversity of drugs allowed us to obtain some
general insight on the kinetic diversity and the number of lumped compartments for
different classes of compounds. Our analysis is based on recent advances in a priori
models for predicting tissue-to-unbound plasma partition coefficients [15, 17].
Rather than grouping drugs according to therapeutic indications, we grouped them
according to their alkalinity/acidity. We find that for weak and moderate-to-strong
bases and for acids with moderate to high fraction unbound, the mechanistically
lumped model typically comprised three to four compartments. For acids with low
fraction unbound, i.e., high plasma protein binding, the lumped model comprised
only a single compartment. For acids, the fraction unbound in plasma is used to
determine the albumin association constant in the model to a priori predict tissue-to-
unbound plasma partition coefficients [17]. From this it follows that acids with low
fup strongly bind to interstitial albumin. This might explain why a 1-compartment
model was sufficient to predict the concentration-time profile of the drug in all
organs and tissues as predicted by the 13-compartment whole-body PBPK.
A first comparison to published classical PK models for analyzing clinical data
showed a good agreement between the number of compartments used and the
number of compartments of our minimal lumped model. For Midazolam and
Thiopental, 2- and 3-compartment models have been used [41–44], while we
predicted a minimal 3-compartment PK model. For Valproate, a 1-compartment
model is reported by [45, 46], which is in agreement with our predictions (see
Fig. 8). For Tolbutamide, a 2-compartment model was used in [47], while
we predicted a minimal 1-compartment model. For Lidocaine, a 2- as well as a
3-compartment model was reported in [3, 48], while we predict a minimal
2-compartment model. Such a comparison can only be preliminary, since it does not
take into account two important facts: the sparsity of the experimental data, and the
variability inherent in the patient cohort of clinical trials. The first fact might result
in a lower number of compartments in the estimated classical model, while the
second fact is likely to result in a larger number of compartments estimated for the
classical model.
In summary, the presented lumping method is the first step towards a more
comprehensive approach to translate knowledge and insight from pre-clinical and
early clinical development—given in form of a whole-body PBPK model—into the
development of classical compartment models. In this article, we focussed on the
static parameter case, i.e., the case of an individuum (including the fictive mean
individuum). The next step will have to consider variability of the type that is
present in patient collectives of clinical trials. In this regard, the development of
methods to generate in silico populations suitable for PBPK modeling [22, 49], and
the development of a methodology to consider parametric variability [13] are
expected to prove useful. This opens the possibility to extend the presented lumping
method to analyze and incorporate covariates and their expected impact into the
lumped model.
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Appendix A: Derivation of the relation between the lumped and the original
concentrations
The relation between the concentrations of the lumped compartment and the
comprised original compartments is given by Eq. 22:
CL ¼ 1
VL
X
tis
VtisCtis: ð54Þ
The idea is to establish a link between the concentration Ctis of one of the original
organs (or tissues) and the concentration CL of the associated lumped compartment.
Let us arbitrarily choose one organ (named ‘ref’). Using the lumping criteria, we
have Ctis/Ktis = Cref/(Kref(1 - Eref)) and thus Ctis = CrefKtis/(Kref(1 - Eref)) for all
tissue/organs lumped into ‘L’. In combination with the above equation for CL this
yielded
CL ¼ 1
VL
X
tis
Vtis
Ktis
Krefð1  ErefÞCref ; ð55Þ
or equivalently
CL ¼ 1
VL
X
tis
VtisKtis  Cref
Krefð1  ErefÞ : ð56Þ
Using the definition of KL in Eq. 23 and 24 we obtain the desired relation:
CL
KL
¼ Cref
Krefð1  ErefÞ : ð57Þ
Since the tissue/organ ‘ref’ was arbitrarily chosen, the above relation holds for every
original compartment ‘tis’ that is part of the lumped compartment ’L’, being
eliminating (in which case Eref [ 0) or non-eliminating (in which case Eref = 0).
Appendix B: General derivation of lumped ODEs
In the following, the subscript tis refers to all organs of the PBPK model excluding
the liver, i.e., adi, bra, bon, gut, hea, kid, lun, mus, ski, spl.
To derive general equations for the rate of change of the lumped concentrations
CL it is advantageous to bring the original ODEs of the generic PBPK in a different
but equivalent form, where elimination is associated with the venous compartment
and all other compartments have the same structural form. In the generic PBPK
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model (see Section ‘Material and Methods’), the liver is assumed to be the only
eliminating organ with ODE (see Eq. 3)
Vliv
d
dt
Cliv ¼ Qliv  Cin  Cliv
Kliv
 
 CLintCliv: ð58Þ
Defining Rhep = CLint Kliv/Qliv and noting that 1 ? Rhep = 1/(1 - Ehep), where
Ehep is the hepatic extraction ratio defined in Eq. 16, we obtain
Vliv
d
dt
Cliv ¼ Qliv  Cin  Cliv
Kliv
 
 QlivRhep Cliv
Kliv
ð59Þ
¼ Qliv  Cin  ð1 þ RhepÞCliv
Kliv
 
ð60Þ
¼ Qliv  Cin  Cliv
Klivð1  EhepÞ
 
: ð61Þ
Now, the inflowing concentration of the vein is given by (see Eq. 7)
Cin ¼ 1
Qco
X
tis
Qtis
Ctis
Ktis
; ð62Þ
which can be rewritten as
Cin ¼ 1
Qco
X
tis 6¼liv
Qtis
Ctis
Ktis
 
þQlivð1  EhepÞ Cliv
Klivð1  EhepÞ
 ð63Þ
¼ 1
Qco
X
tis 6¼liv
Qtis
Ctis
Ktis
þ Qliv Cliv
Klivð1  EhepÞ
 !
 1
Qco
QlivEhep
Cliv
Klivð1  EhepÞ :
ð64Þ
Let us define
bKtis ¼ Ktisð1  EtisÞ; ð65Þ
where Etis denotes the tissue elimination ratio. In our case, it is Eliv = Ehep and
Etis = 0 otherwise. Moreover, formally define bKven ¼ bKart ¼ 1. Then, we finally
obtain an equivalent formulation of the whole-body PBPK model. For all organs,
tissues and other spaces except vein, it is
Vtis
d
dt
Ctis ¼ Qtis  Cin  CtisbKtis
 
; ð66Þ
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while for the vein it is
Vven
d
dt
Cven ¼ Qco  Cin  CvenbKven
 
 CLblood ClivbKliv ; ð67Þ
where we exploit CLblood = QlivEhep based on Eq. 67.
We determined the equation for the rate of change of the lumped concentration
CL by differentiating Eq. 22, yielding:
VL
d
dt
CL ¼
X
tis
Vtis
d
dt
Ctis: ð68Þ
The right hand side Vtisd/dt Ctis is defined in Eqs. 66 and 67. The right hand side of
contain the concentrations of the original PBPK model Ctis, which can be
determined using Eq. 57.
We obtained a very simple form of equations for the mechanistically lumped
model, when spleen and gut were lumped together into the same compartment as the
liver (hence they were part of the lumped ‘Liv’ compartment), and when lung and
artery were lumped together into the same compartment as the vein (hence, they
were part of the lumped ‘cen’ compartment). In this case, the influent concentrations
will be identical for all compartments different from the central compartment. The
rate of change for the concentration of the pre-lumped compartments spl-gut-liv
(‘sgl’) and ven-lun-art (‘vla’) are
Vsgl
d
dt
Csgl ¼ Qliv Cart  ClivbKliv
 
ð69Þ
¼ Qliv Cart  CsglbKsgl
 !
; ð70Þ
and
Vvla
d
dt
Cvla ¼ Qco Cin  CartbKart
 
 CLblood ClivbKliv ð71Þ
¼ Qco Cin  CvlabKvla
 
 CLblood ClivbKliv ð72Þ
where Cin is the concentration flowing into the vein.
Now, we have for any lumped compartment excluding the central compartment:
VL
d
dt
CL ¼
X
tis
Vtis
d
dt
Ctis ð73Þ
¼
X
tis
QtisCart 
X
tis
Qtis
CtisbKtis ; ð74Þ
where the sum is taken over all tissues that are lumped into ‘L’. Our above
assumption (resulting in Eq. 69) ensures that the inflowing concentration is the same
J Pharmacokinet Pharmacodyn (2010) 37:365–405 399
123
and identical to Cart for all tissue/organs. Exploiting the lumping condition Ctis= bK ¼
CL=KL yields
VL
d
dt
CL ¼
X
tis
Qtis
 !
Cin 
X
tis
Qtis
 !
CL
KL
: ð75Þ
Finally, using QL =
P
tisQtis and Cart = Ccen/Kcen results in
VL
d
dt
CL ¼ QL Ccen
Kcen
 CL
KL
 
: ð76Þ
For the central compartment, we obtain analogously
Vcen
d
dt
Ccen ¼ Qcen Cin  CcenbKcen
 
 CLblood CLiv
KLiv
; ð77Þ
where we exploited the fact that Cliv= bKliv ¼ CLiv=KLiv.
The above equations do not take into account any dosing. Again, as in the whole-
body PBPK case, the corresponding ODEs of the lumped compartments comprising
vein and liver have to be amended correspondingly. For an i.v. infusion riv (see Eq.
9 for the definition), it is
Vcen
d
dt
Ccen ¼ Qcen Cin  CcenbKcen
 
 CLblood CLiv
KLiv
þ riv; ð78Þ
while for a p.o. administration rpoðFFGÞ (see Eq. 9 for the definition) it is
VLiv
d
dt
CLiv ¼ QLiv Ccen
Kcen
 CLiv
KLiv
 
þ rpoðFFGÞ: ð79Þ
If ‘cen’ and ‘Liv’ are identical, i.e., the liver is lumped into the central
compartment, then it is Ccen/Kcen = CLiv/KLiv and thus
Vcen
d
dt
Ccen ¼ Qcen Cin  CcenbKcen
 
 CLblood Ccen
Kcen
þ riv;poðFbioÞ: ð80Þ
Note that in this case, the p.o. administration model has to account for the hepatic
extraction, i.e., the absorption model with Fbio = (1 - Ehep)FFG (see Eq. 13) is
used rather then the model with FFG (see Eq. 10).
Appendix C: Lumping of permeability rate-limited tissue model
The rates of change of the vascular concentration Cvas and the tissue concentration
Ctis corresponding to a permeability limited tissue model are given by:
Vvas
d
dt
Cvas ¼ Qtis  ðCin  CvasÞ  PStis Cvas  Ctis
Ktis
 
ð81Þ
Vtis
d
dt
Ctis ¼ PStis  Cvas  Ctis
Ktis
 
: ð82Þ
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The amount of drug that can transfer from the vascular to the tissue part is limited
by the maximal amount of drug, entering the tissue, i.e, QtisCin. This has to be taken
into account, when lumping the tissue space together with other compartments. The
following idea is similar to the approach to determine the blood clearance from the
intrinsic clearance. It is based on a quasi-steady state assumption on Cvas (Eq. 81)
yielding
0 ¼ Qtis  ðCin  CvasÞ  PStis Cvas  Ctis
Ktis
 
ð83Þ
or
Cvas ¼ Qtis
PStis þ Qtis Cin þ
PStis
PStis þ Qtis 
Ctis
Ktis
: ð84Þ
Thus, in steady state, the vascular concentration is a weighted sum of the influent
concentration Cin and the concentration leaving the tissue compartment Ctis/Ktis. For
permeability-rate limited organs, we would usually expect
Qtis
PStis þ Qtis [
PStis
PStis þ Qtis ; ð85Þ
and as a consequence, we lump the vascular compartment with volume Vvas together
with the blood compartment and approximate Cvas = Cblood.
Inserting this formula for Cvas into Eq. 82 for the tissue concentration yields
Vtis
d
dt
Ctis ¼ PStis 
QtisCin þ PStis CtisKtis
PStis þ Qtis 
Ctis
Ktis
 !
ð86Þ
and finally
Vtis
d
dt
Ctis ¼ PStis  Qtis
PStis þ Qtis  Cin 
Ctis
Ktis
 
: ð87Þ
Hence, when lumping the tissue part of a permeability-rate limited tissue model, the
term
PStis  Qtis
PStis þ Qtis ð88Þ
should take the role of the tissue blood flow Qtis. It is bounded by both Qtis and PStis,
as one would expect.
Appendix D: Automated determination of the number of lumped
compartments of the mechanistically lumped model, and its composition
To compare the mechanistically lumped PK compartment models for a number of
different drugs, we used an automated detection algorithm to determine the number
of lumped compartment and its composition. The input were the normalized
concentration-time profiles as predicted by the detailed whole-body PBPK model
(cf. Eq. 19):
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ctisðtÞ ¼ CtisðtÞ
Ktisð1  EtisÞ : ð89Þ
We determined the similarity matrix M = (Mij) with entries
Mi;j ¼
hctisðiÞ; ctisðjÞi
hctisðiÞ; ctisðiÞi
; ð90Þ
where h, i denotes the Euclidian scalar product. In our setting, if Ctis is given as a
vector at different time points ctis(t1), ..., ctis(tM) for some M [ 0, then
hctisðiÞ; ctisðjÞi 
XM
k¼1
ctisðiÞðtkÞ  ctisðjÞðtkÞDt; ð91Þ
where we, for simplicity, assume that the time points are equally spaced with
distance Dt.
Next, we determined the eigenvector v corresponding to the maximal eigenvalue
of M. This eigenvector has an entry corresponding to each organ, tissue or other
space of the whole-body PBPK model. We normalized the eigenvector
wðtisÞ ¼ vðtisÞ
vðvenÞ ð92Þ
such that the normalized eigenvector satisfied w(ven) = 1. See Fig. 15 for the
eigenvector corresponding to our model compound Lidocaine (for sake of
illustration, we ordered the entries in increasing order).
We then considered the smallest entry of w (in the example corresponding to the
muscle tissue) and lumped all organs that satisfied:
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Fig. 15 Normalized eigenvector w corresponding to the maximal eigenvalue of the similarity matrix
M based on the PBPK predictions of an 60 min i.v. infusion of 400 mg Lidocaine
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wðtisÞ\wðmusÞ þ Dw; ð93Þ
with Dw ¼ 0:045. For our model compound Lidocaine, there was no such organ.
Hence, the muscle tissue comprised a single lumped compartment. We proceeded
with the next tissue (adipose in our example):
wðtisÞ\wðadiÞ þ Dw: ð94Þ
In this case, w(bon) was the only organ to satisfy the above inequality so that
adipose and bone were lumped together. We then proceeded with skin etc. The
value of Dw was chosen so that the automated lumping procedure gave the same
results as the manually chosen lumping for Lidocaine. The smaller the value of Dw
the more similar the concentration-time profiles have to be for two organs/tissues to
be lumped together.
For Caffeine, Diazepam and Amobarbital the predicted mechanistically lumped
model was not sufficient to predict all concentration-time profiles of the
13-compartment whole-body PBPK model. In this case, we manually added a
lumped compartment, which resolved the problem and increased the number of
compartments by 1.
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